The infusion of ex vivo, interleukin-15 and -21-activated donor NK cells after haploidentical HCT in high-risk AML and MDS patients—a randomized trial. The infusion of ex vivo, interleukin-15 and -21-activated donor NK cells after haploidentical HCT in high-risk AML and MDS patients—a randomized trial

To understand the cellular landscape of PBMCs of the AML patients after DNKI therapy, we analyzed a totally longitudinal (before DNKI, after 1 and 3 months DNKI therapy) 55,398 PBMC single cells from 4 AML patients by single cell RNA-seq Overall design: 12 single-cell RNA-sequencing data consists of longitudinal (before DNKI, after 1 and 3 months DNKI therapy) PBMCs from 4 AML patients with DNKI therapy